BioLineRx (BLRX) Profit After Tax (2011 - 2025)

BioLineRx's Profit After Tax history runs 14 years deep, the most recent figure standing at -$2.2 million for Q4 2025.

• On a quarterly basis, Profit After Tax rose 29.84% year-over-year to -$2.2 million in Q4 2025; TTM through Dec 2025 was $5.9 million, a 163.49% increase from a year earlier, with the FY2025 full-year figure at -$2.0 million, up 78.03% from the prior year.
• Profit After Tax fell to -$2.2 million in Q4 2025 per BLRX's latest filing, from -$977000.0 in the prior quarter.
• Across five years, Profit After Tax topped out at $18.5 million in Q2 2023 and bottomed at -$16.0 million in Q3 2023.
• The 5-year median for Profit After Tax is -$3.7 million (2021), against an average of -$2.5 million.
• Across the five-year window, Profit After Tax tumbled 146.69% in 2023 and surged 836.64% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$4.3 million in 2021, then sank by 33.16% to -$5.7 million in 2022, then plunged by 142.26% to -$13.9 million in 2023, then jumped by 77.05% to -$3.2 million in 2024, then climbed by 29.84% to -$2.2 million in 2025.
• Per Business Quant, the three latest BLRX Profit After Tax figures stand at -$2.2 million (Q4 2025), -$977000.0 (Q3 2025), and $3.9 million (Q2 2025).